| Mortality | Adverse Events | Neurosurgical Intervention | Rebleeding | Mean hemorrhage volume | |||||
---|---|---|---|---|---|---|---|---|---|---|
 | RR, 95% | P-Value | RR, 95% | P-Value | RR, 95% | P-Value | RR, 95% | P-Value | RR, 95% | P-Value |
Study design | ||||||||||
 Multisite RCT | 0.99 [0.79–1.24] | 0.90 | 0.91 [0.73–1.13] | 0.38 | 1.01 [0.61–1.55] | 0.96 | 0.81 [0.59–1.10] | 0.17 | -0.08 [-0.32, 0.16] | 0.52 |
 Single site RCT | 1.03 [0.73–1.43] | 0.88 | 1.07 [0.39–2.88] | 0.90 | 1.15 [0.89–1.48] | 0.29 | 1.65 [0.94–2.89] | 0.88 | -0.46 [-0.72, -0.20] | 0.0005 |
Enrollment time after trauma | ||||||||||
 < 3 h | 0.94 [0.87–1.02] | 0.15 | 0.91 [0.77–1.08] | 0.28 | 1.18 [0.89–1.55] | 0.24 | 0.91 [0.75–1.10] | 0.34 | -0.50 [-0.94, -0.05] | 0.03 |
 > 3 h | 0.76 [0.51–1.11] | 0.15 | 2.45 [0.92–6.52] | 0.07 | 1.00 [0.70–1.44] | 0.99 | 1.14 [0.65–2.02] | 0.64 | -0.33 [-0.65, 0.00] | 0.05 |
TXA dose | ||||||||||
 2 g TXA bolus followed by a placebo infusion | 0.80 [0.56–1.15] | 0.22 | 1.22 [0.85–1.74] | 0.28 | N/A | N/A | 1.24 [0.91–1.70] | 0.17 | N/A | N/A |
 1 g TXA bolus followed by 1 g TXA maintenance | 1.01 [0.82–1.24] | 0.95 | 1.00 [0.92–1.08] | 0.97 | N/A | N/A | 1.00 [0.71–1.41] | 1 | N/A | N/A |